

**References for the MDS Symposium: The Diagnosis, Classification, and Clinical Care of Myelodysplastic Syndromes (DC³-MDS)
ASCP 2013 Annual Meeting
September 20, 2013 3:15pm-6:15pm**

Slide 23

Swerdlow S, Campo E, Harris NL, et al, eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC; 2008.

NCCN Guidelines: myelodysplastic syndromes. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed October 4, 2013.

Slide 45

Baur AS, Meugé-Moraw C, Schmidt P-M, Parlier V, Jotterand M, Delacrétaç F. CD34/QBEND 10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes [published online December 25, 2001]. *Eur J Haematol*. 2000;64(2):71-79. doi:10.1034/j.1600-0609.2000.90047.x.

Soligo DA, Oriani A, Annaloro C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes [published online July 11, 2006]. *Am J Hematol*. 1994;46(1):9-17. doi:10.1002/ajh.2830460103.

Wu W, Ngan D, Pullarkat ST. Strong expression of chemokine receptor CCR9 in B-cell lymphomas involving the gastrointestinal tract. *Mod Pathol*. 2012;25(suppl. 2):381A.

Naresh KN, Lampert IA. CD117 Expression as an aid to identify immature myeloid cells and foci of ALIP in bone marrow trephines [letter] [published online December 20, 2005]. *Am J Hematol*. 2006;81(1):79. doi: 10.1002/ajh.20466.

Slide 49

Howe RB, Porwit-MacDonald, Wanat W, Tehranchi R, Hellström-Lindberg E. Clinical observations, interventions and therapeutic trials: the WHO classification does make a difference. *Blood*. 2004;103(9):3265-3270. doi:10.1182/blood-2003-06-2124.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Naqvi K, Jabbour E, Bueso-Ramos, et al. Implications of discrepancy in morphologic diagnosis of myeloplastic syndrome between referral and tertiary care centers. *Blood*. 2011;118(17):4690-4693. doi:10.1182/blood-2011-03-342642.

Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes [published online October 12, 2012]. *Haematologica*. 2013;98(4):568-575. doi:10.3324/haematol.2012.071449.

Parmentier S, Schetelig J, Lorenz K, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. *Haematologica*. 2012;97(5):723-730. doi:10.3324/haematol.2011.056879.

Slide 50

Valent P, Orazi A, Büsche G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). *Oncotarget*. 2010;1(7):483-496.

Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS [published online September 15, 2011]. *Leuk Res*. 2012;36(1):1-5. doi:10.1016/j.leukres.2011.08.016.

Valent P, Fonatsch C, Stindl R, et al. Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. *Leuk Res*. 2004(6);28:651-655. doi:10.1016/j.leukres.2003.10.023.

Valent P, Jäger E, Mitterbauer-Hohendanner, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. *Am J Cancer Res*. 2011;1(4):531-541.

Slide 54

Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference [published online March 7, 2011]. *Leuk Res*. 2007;31(6):727-736. doi:10.1016/j.leukres.2006.11.009.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Schroeder L, Ruf A, Bernhardt B, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. *Ann Oncol.* 2010;21(11):2267-2271. doi:10.1093/annonc/mdq233.

Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS [published online September 15, 2011]. *Leuk Res.* 2012;36(1):1-5. doi:10.1016/j.leukres.2011.08.016.

Slide 62

Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow [published online April 13, 2006]. *Leukemia.* 2006;20(7):1319-1321. doi:10.1038/sj.leu.2404215.

Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of *JAK2*, *MPL* and *IDH* mutations [published online May 20, 2010]. *Leukemia.* 2010;24(7):1283-1289. doi:10.1038/leu.2010.105.

Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. *JAK2V617F* Mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones [published online March 7, 2011]. *Leuk Res.* 2010;34(6):821-823. doi:10.1016/j.leukres.2009.09.016.

Slide 63

Jädersten M, Saft L, Smith A, et al. *TP53* Mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression [published online April 25, 2011]. *J Clin Oncol.* 2011;29(15):1971-1979. doi:10.1200/JCO.2010.31.8576.

Kulasekararaj AG, Smith AE, Mian SA, et al. *TP53* mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis [published online January 9, 2013]. *Br J Haematol.* 2013;160(5):660-672. doi:10.1111/bjh.12203.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Slide 68

Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myeloplastic syndrome with increased marrow fibrosis: a distinct clinic-pathological entity [published online March 12, 2008]. *Br J Haematol*. 1991;78(2):161-166. doi:10.1111/j.1365-2141.1991.tb04411.x.

Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes [published online December 22, 2008]. *J Clin Oncol*. 2009;27(5):754-762. doi:10.1200/JCO.2008.18.2246.

Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes [published online November 22, 2007]. *Leukemia*. 2008;22(2):313-322. doi:10.1038/sj.leu.2405030.

Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients [published online April 24, 2009]. *Eur J Haematol*. 1992;48(4):208-214. doi:10.1111/j.1600-0609.1992.tb01587.x.

Kröger N, Zabelina T, van Biezen, et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis [published online October 22, 2010]. *Haematologica*. 2011;96(2):291-297. doi:10.3324/haematol.2010.031229.

Slide 72

Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin [published online May 17, 2007]. *Leukemia* 2007 21(7):1436-1441. doi:10.1038/sj.leu.2404747.

Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy [published online April 14, 2008]. *J Clin Oncol*. 2008;26(15):2505-2511. doi:10.1200/JCO.2007.11.9214.

Passweg JR, Giagounidis AAN, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/39 [published online December 13, 2010]. *J Clin Oncol*. 2011;29(3):303-309. doi:10.1200/JCO.2010.30.6829.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Orazi A, Abitar M, Heerema NA, Haskins S, Neiman RS. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. *Am J Clin Pathol*. 1997;107(3):268-274.

Afable MG II, Wlodarski M, Makishima H, et al. SNP array–based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes [published online April 28, 2011]. *Blood*. 2011;117(25):6876-6884. doi:10.1182/blood-2010-11-314393.

Slide 76

Cheson BD, Bennett, JM, Kantarjian, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. *Blood*. 2000;96(12):3671-3674.

Mazzella FM, Smith D, Horn P, et al. Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients [published online June 5, 2006]. *Am J Hematol*. 2006;81:484-491. doi:10.1002/ajh.20563.

Wang SA, Tang G, Fadare O, et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification [published online September 12, 2008]. *Mod Pathol*. 2008;21(11):1394-1402. doi:10.1038/modpathol.2008.142.

Bacher U, Haferlach C, Alpermann R, Kern W, Schnittger S, Haferlach T. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells [published online May 23, 2011]. *Haematologica*. 2011;96(9):1284-1292. doi:10.3324/haematol.2011.043687

Slide 137

McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia [published online December 3, 2012]. *Blood*. 2013;121(6):975-983. doi:10.1182/blood-2012-04-426965.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Slide 139

Smith SM, Le Beau MM, Dezheng Hou, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. [published online March 6, 2003]. *Blood*. 2003;102(1):43-52. doi:10.1182/blood-2002-11-3343.

Slide 140

Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge [published online February 13, 2012]. *J Clin Oncol*. 2012;30(8):820-829. doi:10.1200/JCO.2011.35.6394.

Slide141

Greenberg PL, Tuechler H, Schanz, J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes [published online June 27, 2012]. *Blood*. 120(12):2454-2465. doi:10.1182/blood-2012-03-420489.

Slide 144

Jerez A, Lukasz P, Gondek AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited [published online February 27, 2012]. *J Clin Oncol*. 2012;30(12):1343-1349. doi:10.1200/JCO.2011.36.1824.

Slide 160

Bennett JM, Catovsky MT, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. *Br J Haematol*. 1982;51(2):189-199.

Slide 162

Adapted from: Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [published online April 8, 2009]. *Blood*. 2009;114(5):937-951. doi:10.1182/blood-2009-03-209262.

Slide 163

Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making [published online September 26, 2005]. *J Clin Oncol*. 2005;23(30):7594-7603. doi:10.1200/JCO.2005.01.7038.

Slides 166-168

Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for Evaluating Prognosis in myelodysplastic syndromes [published correction appears in *Blood*. 1998(91)3:1100]. *Blood*. 1997;89(6):2079-2088.

Slides 169-171

Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge [published online February 13, 2012]. *J Clin Oncol*. 2012;30(8):820-829. doi:10.1200/JCO.2011.35.6394.

Slides 174-177

Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes [published online June 27, 2012]. *Blood*. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489.

Slide 183

Sekeres MA, Stowell SA, Berry CA, et al. Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative [published online January 10, 2013]. *Leuk Res*. 2013;37(4):422-426. doi:10.1016/j.leukres.2012.12.009.

Slides 184-185

Ades L, Lamarque M, Raynaud S, et al. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of MDS patient treated with azacitidine (AZA): the Groupe Francophone des Myelodysplasies (GFM) experience [abstract 422]. *Blood* (ASH annual meeting abstracts). 2012;120(21):422.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Ades L, de Renzis B, Jeddi R, et al. Azacitidine (AZA) combined with idarubicin in untreated patients with high risk MDS—results of a phase I/II study of the Groupe Francophone des Myelodysplasies [abstract 1720]. *Blood* (ASH annual meeting abstracts). 2012;120(21):1720.

Slide 186

Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System [published online July 10, 2008]. *Cancer*. 2008;113(6):1351-1361. doi:10.1002/cncr.23697.

Slide 187

Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System [published online July 10, 2008]. *Cancer*. 2008;113(6):1351-1361. doi:10.1002/cncr.23697.

Hugo SE, Bundrick SC, Hanson CA, Steensma DP. Independent validation of the MD Anderson Cancer Center risk model for myelodysplastic syndromes (MDS), and comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization–based Prognostic Scoring System (WPSS) [ASH abstract 3814]. *Blood* (ASH annual meeting abstracts). 2009;114(22): 3814

Corrales-Yepe M, Lancet JE, List AF, et al. Validation of the newly proposed MD Anderson Prognostic risk model for patients with myelodysplastic syndromes [abstract 444]. *Blood* (ASH annual meeting abstracts). 2010;116(21):444.

Slide 188

Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome [published online December 13, 2007]. *Leukemia*. 2008;22(3):38-543. doi:10.1038/sj.leu.2405070.

Slide 189

Sekeres MA, Elson P, Tiu RV, et al. Validating the lower-risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for patients with myelodysplastic syndromes [abstract 1720]. *Blood* (ASH annual meeting abstracts). 2011;118(21):1720.

References for the MDS Symposium: ASCP 2013 Annual Meeting, September 20, 2013 Continued

Slides 190-192

Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes [published online August 6, 2012]. *J Clin Oncol*. 2012;30(27):3376-3382. doi:10.1200/JCO.2011.40.7379.

Slide 193

Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies [published online February 1, 2011]. *Blood*. 2011;117(17):4552-4560. doi:10.1182/blood-2010-07-295857.

Slide 195

Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes [published online June 27, 2012]. *Blood*. 120(12):2454-2465. doi:10.1182/blood-2012-03-420489.

Slide 204

List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *N Engl J Med*. 2006;355(14):1456-1465. doi:10.1056/NEJMoa061292.

Slide 205

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life [published online March 18, 2003]. *Br J Haematol*. 2003;120(6):1037-1046. doi: 10.1046/j.1365-2141.2003.04153.x.

Slide 209

Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol*. 2002;20(10):2429-2440. doi:10.1200/JCO.2002.04.117.

Slide 210

Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study [published online February 21, 2009]. *Lancet Oncol.* 2009;10(3):223-232. doi:10.1016/S1470-2045(09)70003-8.

Slide 211

Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. *J Clin Oncol* 2009;27(23):3842-3848. doi:10.1200/JCO.2008.19.6550.

Slide 215

Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome [published online March 23, 2004]. *Blood.*2004;104(2):579-585. doi:10.1182/blood-2004-01-0338.

Slide 216

Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis [published online June 24, 2013]. *J Clin Oncol.* 2013;31(21):2662-2670. doi:10.1200/JCO.2012.46.8652.